Deals
China Biotech I-Mab Is Said to Target Up to $500 Million in IPO
- Drug developer aims to file listing application next week
- Company joins wave of biotech offerings on Hong Kong bourse
This article is for subscribers only.
Chinese drug developer I-Mab Biopharma Co. is poised to seek approval for a Hong Kong initial public offering that could raise as much as $500 million, according to people with knowledge of the matter.
The Shanghai-based company plans to submit an application to the Hong Kong stock exchange next week, the people said, asking not to be identified because the information is confidential. I-Mab aims to complete the share sale by the end of the year, they said.